I centri RISP (Rete Italiana Screening Polmonare) sono strutture sanitarie […]
Search Results for: Un biomarcatore segnala il rischio di demenza 5-10 anni prima dei sintomi
Here's what we've found for you
Liguria
I centri RISP (Rete Italiana Screening Polmonare) sono strutture sanitarie […]
Linee guida per la sindrome genitourinaria della menopausa
Una nuova linea guida multi-organizzativa presenta 26 raccomandazioni per il […]
Bollini arancioni domenica in 6 città, rischio caldo per i fragili
Oltre a Palermo e Perugia, Bari, Cagliari, Campobasso e Roma
Bollini arancioni domenica in 6 città, rischio caldo per fragili
Oltre a Palermo e Perugia, Bari, Cagliari, Campobasso e Roma
Vancomicina orale come profilassi: una speranza contro le recidive di infezione da C. difficile [Gastroenterologia ed epatologia]
Un nuovo studio clinico randomizzato, pubblicato su JAMA Network Open, suggerisce che la vancomicina orale potrebbe ridurre il rischio di recidiva dell’infezione da Clostridioides difficile nei pazienti ad alto rischio in terapia antibiotica. Nonostante i risultati non siano statisticamente significativi, gli esperti sottolineano l’importanza di ulteriori ricerche su questa strategia preventiva.
Controllo pressorio nelle 24 ore: dati comparativi sull'associazione olmesartan-amlodipina [Cardio]
Uno studio pubblicato recentemente su “JAMA Network Open” ha dimostrato che la somministrazione serale dell’associazione olmesartan-amlodipina garantisce un controllo superiore della pressione arteriosa sistolica notturna rispetto al dosaggio mattutino, con una riduzione media significativamente maggiore e senza incremento del rischio di ipotensione.
Tumori gastrointestinali in aumento tra gli under 50
Per nati 1990 rischio doppio a colon. Pesa cibo, alcol,poco moto
Crescono tumori gastrointestinali tra under-50,in 10 anni +14,8%
Per nati 1990 rischio doppio di cancro colon
Adozione delle istruzioni applicative relative alle procedure di rilascio dell’AIC e alle modalità per adempiere agli obblighi di legge, anche relativamente ai medicinali di importazione e distribuzione parallela
Con Determinazione DTS 56-2025 sono state adottate dall’Agenzia le istruzioni applicative relative alle procedure di rilascio dell’AIC e alle modalità per adempiere agli obblighi previsti dall’art. 4 del d.lgs. 6 febbraio 2025, n. 10, anche relativamente ai medicinali di importazione e distribuzione parallela.
Randomized, Proof-of-Concept Trial (RESCUE) of RNS60 as an Adjunct Therapy in Acute Ischemic Stroke
Stroke, Ahead of Print. BACKGROUND:Despite significant improvements in early reperfusion, many patients with acute ischemic stroke with large vessel occlusion experience poor outcomes, which indicates a clear need for adjunct therapies. RNS60 is a proprietary combination of oxygen supersaturated in saline with cerebroprotective and immunomodulatory effects. RNS60 showed therapeutic promise in rodent and nonhuman primate models of acute ischemic stroke. RESCUE was the proof-of-concept trial testing adjunctive treatment with RNS60 in patients with acute ischemic stroke with large vessel occlusion undergoing endovascular thrombectomy with or without prior treatment with an intravenous thrombolytic.METHODS:This randomized multicenter, placebo-controlled, double-blind, phase 2 study enrolled 82 participants, assigned 1:1:1 to 48-hour infusion of RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, or placebo 1.0 mL/kg per hour, and followed for 90 days. Rates of serious adverse events and mortality were the primary end points. Efficacy end points included the modified Rankin Scale score, infarct volume growth, National Institutes of Health Stroke Scale, worsening of stroke, Barthel Index, and the EuroQoL health-related quality of life scale.RESULTS:The RNS60 groups met the primary end points with similar rates of serious adverse events (33.3%, 25.0%, and 28.6%) and fewer deaths (6.7%, 8.3%, and 14.3%) across RNS60 0.5 mL/kg per hour, RNS60 1.0 mL/kg per hour, and placebo, respectively. The RNS60 1.0 mL/kg per hour group showed reduced infarct growth by 47% at 48 hours post–endovascular thrombectomy (21.4 mL [interquartile range, 5.0–29.1] versus 40.6 mL [interquartile range, 6.3–62.3];P
Neurodevelopmental Outcomes in Early Adolescence: The Pediatric Heart Network Single Ventricle Reconstruction Trial
Circulation, Ahead of Print. BACKGROUND:Neurodevelopmental and functional impairments are among the most consequential morbidities for survivors of hypoplastic left heart syndrome after staged single ventricle surgical palliation. The SVRIII trial (Long-Term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type) enrolled adolescents, who were randomized to different surgical shunt types at the time of Norwood procedure as neonates, for multifaceted in-person evaluation. This study reports their neurodevelopmental outcomes.METHODS:Transplant-free survivors from SVRIII were invited to complete an in-person comprehensive neurodevelopmental evaluation in early adolescence. Outcomes across domains of cognition, academics, learning, memory, and attention, as well as social, emotional, behavioral, adaptive, and executive function, were compared with those of normative populations. Associations with demographic and medical covariates, including Norwood shunt type, were also assessed.RESULTS:Among 549 participants enrolled in the SVR trial (Single Ventricle Reconstruction), 200 of the 237 SVRIII participants (84%) completed a neurodevelopmental evaluation at a mean age of 11 years (range, 10 to 14 years). SVRIII participants who did versus did not undergo evaluation were more likely to be male (63% versus 51%), to be White (87% versus 76%), and to have a higher Childhood Opportunity Index score (61±26 versus 46±39). Full-scale intelligence quotient (88±18) was significantly lower than in the normative population, with 39% >1 and 15% >2 SD below the normative mean. Similar patterns were seen for reading (38% >1 SD and 16% >2 SD below the normative mean) and math (38% >1 SD and 19% >2 SD below the normative mean) scores. Attention, executive functioning, social development, visual memory, and adaptive functioning were all more impaired than in the normative population. Measures of socioeconomic status, number of medical complications, and requirement for a gastrostomy tube were each independent predictors of neurodevelopment, with socioeconomic status the most consistently significant factor across models. Group differences by shunt type were inconsistent across neurodevelopmental domains without a clear benefit of one surgical strategy.CONCLUSIONS:In early adolescence, transplant-free survivors of surgical palliation for hypoplastic left heart syndrome show concerning impairments across all domains of neurodevelopment. The distribution of affected outcomes is broad and associated with demographic, medical, and, most frequently, socioeconomic factors. Our findings support recommendations for neurodevelopmental evaluation during adolescence to guide individualized interventions to promote educational success and psychosocial well-being.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT02455531.
Vaccinazione come strategia integrata nella prevenzione cardiovascolare, consensus ESC [Cardio]
Una dichiarazione di consenso della European Society of Cardiology (ESC), pubblicata sull’European Heart Journal, ha definito le vaccinazioni contro influenza, pneumococco e SARS-CoV-2 come interventi efficaci nella riduzione del rischio di eventi cardiovascolari, proponendole come quarto pilastro della prevenzione, accanto agli antipertensivi, ai farmaci ipolipemizzanti e ai trattamenti per il diabete.
Rivalutazione delle strategie di sospensione degli antidepressivi: una revisione sistematica [Neurologia e Psichiatria]
Uno studio pubblicato su “JAMA Psychiatry” ha analizzato la comparsa e l’intensità dei sintomi da sospensione degli antidepressivi, sollevando dubbi sulla necessità di strategie di riduzione graduale di lunga durata.
Tirzepatide: riduzione del rischio cardiovascolare nello scompenso cardiaco senza diabete [Cardio]
In uno studio retrospettivo pubblicato sulla rivista “Current Problems in Cardiology”, è stata riscontrata una riduzione significativa dell’incidenza di scompenso cardiaco acuto e di eventi cardiovascolari maggiori nei pazienti non diabetici trattati con tirzepatide.
PPARγ Agonists Accelerate MRI Signal Resolution Mediated by Resting-State Astroglia in Acute Intracerebral Hemorrhage
Stroke, Ahead of Print. BACKGROUND:In the aftermath of intracerebral hemorrhage (ICH), the clearance of harmful substances from the hematoma helps to mitigate brain edema and reduce the risk of subsequent neurological damage. This study aimed to investigate the mechanism underlying early hematoma processing following ICH and to explore the potential of modulating this process via astrocyte regulation.METHODS:ICH was induced by intrastriatal injection of bacterial collagenase. A calcium channel blocker, pyr3, was used to suppress astrocyte activity, or combined with PPARγ (peroxisome proliferator-activated receptor gamma) agonists (rosiglitazone and pioglitazone) as the intervention approach. The rats were randomly assigned to the following groups: ICH with vehicle treatment, ICH with pyr3 treatment, ICH with rosiglitazone treatment, ICH with pioglitazone treatment, ICH with pyr3 and rosiglitazone treatment, and ICH with pyr3 and pioglitazone treatment. Drugs were administered via the intraventricular route into the contralateral ventricle 10 minutes after ICH induction. The evolution of hematoma within the first 21 hours was meticulously examined using T2-weighted magnetic resonance imaging. Motor behavioral testing and diffusion-weighted imaging were used to assess longer-lasting functional outcomes and edema. To assess astrocyte-specific responses, an astrocyte cell line was incubated with hemin followed by different drug treatments. An intracellular hemin assay was used to quantify the hemin uptake capacity of astrocytes.RESULTS:Delayed signaling transitions of the hematoma were observed in the ICH with pyr3 treatment group in T2-weighted images, manifesting in different ICH models (ANOVA;P